Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial

Objective— To determine whether tight glycemic control can be obtained using intensive conventional split-dose insulin therapy in the outpatient management of type II diabetes without development of unacceptable side effects. Research Design and Methods— Fourteen type II diabetic subjects were treated with an intensive program of conventional insulin (subcutaneous NPH and regular insulin before breakfast and supper) for 6 mo. Insulin dose adjustments were based on an algorithm built on frequent CPG measurements (4–6 times/day). Patients were monitored biweekly as outpatients and admitted 1 day/mo for metabolic evaluation. Results— Glycemic control was achieved by 1 mo (mean plasma glucose fell from 17.5 ± 0.9 to 7.7 ± 0.7 mM, P < 0.001) and remained in this range thereafter. Hypoglycemic events at 1 mo were infrequent (mean ± SE events per patient per month: 4.1 ± 0.3) and mild in nature, and progressively decreased to 1.3 ± 0.5 events/mo by 6 mo. After treatment, basal HGO fell 44% from 628 ± 44 to 350 ± 17 μmol·m−2·min−1 (P < 0.001), and maximal rates of glucose disposal measured by hyperinsulinemic euglycemic clamp (1800 pmol·m−2·min−1) improved from 1418 ± 156 to 1657 ± 128 μmol·m−2·min−1 (P < 0.05). The total dose of exogenous insulin required was 86 ± 13 U at 1 mo and 100 ± 24 U at 6 mo. During treatment, mean serum insulin levels increased from 308 ± 80 to 510 ± 102 pM (P < 0.05), while body weight increased from 93.5 ± 5.8 to 102.2 ± 6.8 kg (P < 0.001). Both pre- and posttreatment glucose disposal rates correlated with the total exogenous insulin dose required to achieve glycemic control (r = −0.75 and −0.78, both P < 0.005). Weight gain was inversely related to the pretreatment glucose disposal rate (r = −0.53, P < 0.05) and directly correlated with both mean day-long serum insulin level (r = 0.67, P < 0.01) and total exogenous insulin dose (r = 0.62, P < 0.02). Conclusions— Intensive CIT, when combined with CBG measurements, can be used to rapidly improve glycemic control in type II diabetes without development of unacceptable hypoglycemia. This degree of metabolic improvement, however, requires large doses of exogenous insulin to overcome peripheral insulin resistance and results in greater hyperinsulinemia with progressive weight gain.

[1]  R. Robertson,et al.  Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects. , 1991, JAMA.

[2]  H. Arnqvist,et al.  Effect of Conventional and Intensified Insulin Therapy on Free-Insulin Profiles and Glycemic Control in NIDDM , 1992, Diabetes Care.

[3]  N. Oakley,et al.  Combined Use of Regular and Crystalline Protamine (NPH) Insulins in the Treatment of Severe Diabetes , 1966, Diabetes.

[4]  J. Mann,et al.  Difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin. , 1984, British medical journal.

[5]  R. Tattersall,et al.  Comparison of high fibre diets, basal insulin supplements, and flexible insulin treatment for non-insulin dependent (type II) diabetics poorly controlled with sulphonylureas. , 1988, BMJ.

[6]  M. Taskinen,et al.  Insulin Therapy Induces Antiatherogenic Changes of Serum Lipoproteins in Noninsulin‐Dependent Diabetes , 1988, Arteriosclerosis.

[7]  B. Desbuquois,et al.  Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. , 1971, The Journal of clinical endocrinology and metabolism.

[8]  R. DeFronzo The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[9]  L. Mandarino,et al.  Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. , 1988, Metabolism: clinical and experimental.

[10]  A. Cherrington,et al.  Gluconeogenesis: methodological approaches in vivo. , 1977, Federation proceedings.

[11]  W. J. Andrews,et al.  Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal , 1984, Diabetes.

[12]  M. Taskinen,et al.  Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM , 1990, Diabetes.

[13]  M. Funnell,et al.  Feasibility of Adjustment of Insulin Dose by Insulin-Requiring Type II Diabetic Patients , 1990, Diabetes Care.

[14]  Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.

[15]  J. A. Scarlett,et al.  Insulin Treatment Reverses the Insulin Resistance of Type II Diabetes Mellitus , 1982, Diabetes Care.

[16]  S. Genuth Insulin Use in NIDDM , 1990, Diabetes Care.

[17]  J. Galloway Treatment of NIDDM With Insulin Agonists or Substitutes , 1990, Diabetes Care.

[18]  Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. , 1982, Diabetes.

[19]  M. Riddle Evening Insulin Strategy , 1990, Diabetes Care.

[20]  R. Holman,et al.  Insulin Use in NIDDM: Rationale Based on Pathophysiology of Disease , 1990, Diabetes Care.

[21]  R. Henry,et al.  Effect of Hyperinsulinemia and Hyperglycemia on Intracellular Glucose and Fat Metabolism in Healthy Subjects , 1990, Diabetes.

[22]  R. Rizza,et al.  Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. , 1986, The New England journal of medicine.

[23]  H. Ginsberg,et al.  Effect of Insulin Therapy on Insulin Resistance in Type II Diabetic Subjects: Evidence for Heterogeneity , 1981, Diabetes.

[24]  G. Reaven,et al.  Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. , 1986, The Journal of clinical endocrinology and metabolism.

[25]  Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. , 1991, The American journal of medicine.

[26]  Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial , 1988, Diabetes Care.

[27]  R. Hamman,et al.  The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus , 1985, Diabetes.

[28]  H. Arnqvist,et al.  Effect of different insulin regimens on plasma lipoprotein and apolipoprotein concentrations in patients with non-insulin-dependent diabetes mellitus. , 1990, Atherosclerosis.

[29]  B. Jaffe,et al.  Methods of Hormone Radioimmunoassay , 1974 .

[30]  G. Zahnd Hypoglycemia--mechanisms and prevention in NIDDM treatment with insulin. , 1988, Diabetes research and clinical practice.

[31]  J. Godine,et al.  Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. , 1988, Annals of internal medicine.

[32]  P. Savage,et al.  Role of Cardiovascular Risk Factors in Prevention and Treatment of Macrovascular Disease in Diabetes , 1989, Diabetes Care.